NCT03926936 - FUlvestrant in Gynecological Cancers That Are Potentially Hormone Sensitive: the FUCHSia Study | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 13, 2019

Primary Completion Date

April 1, 2022

Study Completion Date

December 27, 2022

Conditions

Endometrial Stromal SarcomaAdenosarcoma of UterusLeiomyosarcoma UterusEndometrial CancerSex Cord Stromal TumorSerous Ovarian Tumor

Interventions

DRUG

Fulvestrant

intramuscular injection (2x 250mg), once every 2 weeks for the first month, and then monthly until completion of the study

Trial Locations (14)

1000

Amsterdam University Medical Centers (AMC), Amsterdam

The Netherlands Cancer Institute (NKI) - Antoni van Leuwenhoek Hospital (NKI-AvL), Amsterdam

2650

UZ Antwerp, Edegem

2800

AZ Sint Maarten, Mechelen

4030

CHU de Liege, Grivegnée

9000

UZ Gent, Ghent

6525 GA

Gynaecological Oncology, Radboudumc, Nijmegen

6202 AZ

medical Oncology, Maastricht University Medical Centrum+, Maastricht

5623 EJ

Gynecological Oncology Centrum, Catharina Ziekenhuis, Eindhoven

2333 ZA

Department of Obstetrics and Gynaecology, Leiden University Medical Center, Leiden

3075 EA

Gynaecological Oncology, Erasmus MC Cancer Institute, Rotterdam

9713 GZ

Center for Medical Imaging, University Medical Centrum Groningen, Groningen

Obstetrics and Gynaecology, University Medical Centrum Groningen, Groningen

3584 CX

University Medical Centrum Utrecht, Utrecht

All Listed Sponsors

collaborator

Kom Op Tegen Kanker

OTHER

collaborator

Research Foundation Flanders

OTHER

lead

Frederic Amant

OTHER